DK0406856T3 - Stabiliseret FGF-komposition og fremstilling heraf - Google Patents

Stabiliseret FGF-komposition og fremstilling heraf

Info

Publication number
DK0406856T3
DK0406856T3 DK90112850.4T DK90112850T DK0406856T3 DK 0406856 T3 DK0406856 T3 DK 0406856T3 DK 90112850 T DK90112850 T DK 90112850T DK 0406856 T3 DK0406856 T3 DK 0406856T3
Authority
DK
Denmark
Prior art keywords
fgf protein
stabilized
composition
preparation
water
Prior art date
Application number
DK90112850.4T
Other languages
English (en)
Inventor
Yohko Akiyama
Minoru Yoshioka
Nobuyuki Kitamori
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DK0406856T3 publication Critical patent/DK0406856T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90112850.4T 1989-07-07 1990-07-05 Stabiliseret FGF-komposition og fremstilling heraf DK0406856T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17622889 1989-07-07
JP13633390 1990-05-24

Publications (1)

Publication Number Publication Date
DK0406856T3 true DK0406856T3 (da) 1994-07-04

Family

ID=26469955

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90112850.4T DK0406856T3 (da) 1989-07-07 1990-07-05 Stabiliseret FGF-komposition og fremstilling heraf

Country Status (14)

Country Link
US (1) US5189148A (da)
EP (1) EP0406856B1 (da)
JP (1) JP2536247B2 (da)
CN (1) CN1049106A (da)
AT (1) ATE102044T1 (da)
AU (1) AU632344B2 (da)
CA (1) CA2020654A1 (da)
DE (1) DE69006947T2 (da)
DK (1) DK0406856T3 (da)
ES (1) ES2062206T3 (da)
FI (1) FI903440A7 (da)
HU (1) HU205862B (da)
IE (1) IE902470A1 (da)
NO (1) NO902995L (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5500409A (en) * 1990-10-01 1996-03-19 Thomas Jefferson University Method for inhibiting collagen synthesis by keloid fibroblasts
TW209174B (da) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
DE4121043A1 (de) * 1991-06-26 1993-01-07 Merck Patent Gmbh Knochenersatzmaterial mit fgf
EP0539087A1 (en) * 1991-10-21 1993-04-28 Merck & Co. Inc. Stabilized topical acidic fibroblast growth factor formulation
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DE4242889A1 (de) * 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen mit Knochenwachstumsfördernder Füllung
JP3349535B2 (ja) * 1993-01-12 2002-11-25 フロイント産業株式会社 球形顆粒の製造方法
US5331095A (en) * 1993-04-12 1994-07-19 Scios Nova Inc. Process for purification of basic fibroblast growth factor
WO1994027630A1 (en) * 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Cross-linked gelatin gel preparation containing basic fibroblast growth factor
TW282403B (da) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd
WO1998009645A1 (en) * 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US5851579A (en) * 1996-10-28 1998-12-22 Eastman Chemical Company Aqueous enteric coating compositions
WO2000074501A1 (en) * 1999-06-07 2000-12-14 Fibersugar Aps Particulate fibre composition
US20030228288A1 (en) 1999-10-15 2003-12-11 Scarborough Nelson L. Volume maintaining osteoinductive/osteoconductive compositions
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US9387094B2 (en) 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
US7323193B2 (en) 2001-12-14 2008-01-29 Osteotech, Inc. Method of making demineralized bone particles
EP2295088B1 (en) * 2001-10-12 2016-12-07 Warsaw Orthopedic, Inc. Improved bone graft
FR2836011B1 (fr) * 2002-02-20 2004-05-14 Goemar Lab Sa Agent pour la stimulation des defenses naturelles des plantes et procede pour sa mise en oeuvre
KR100981443B1 (ko) * 2002-04-01 2010-09-13 가켄 세야쿠 가부시키가이샤 염기성 선유 아세포 증식 인자 함유 치과용 점조 제제
KR20060031808A (ko) 2003-06-11 2006-04-13 오스테오테크, 인코포레이티드 뼈 임플란트 및 그의 제조 방법
US7824711B2 (en) 2003-12-11 2010-11-02 Isto Technologies, Inc. Particulate cartilage system
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
JP5292533B2 (ja) 2005-08-26 2013-09-18 ジンマー・インコーポレイテッド インプラントおよび関節疾患の治療、置換および治療方法
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
AU2008240191B2 (en) * 2007-04-12 2013-09-19 Zimmer, Inc. Compositions and methods for tissue repair
KR20110086045A (ko) 2008-10-24 2011-07-27 오스테오테크, 인코포레이티드 뼈 형성 촉진용 조성물 및 뼈 형성 촉진방법
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AU2013240972A1 (en) * 2012-03-30 2014-10-30 Ajinomoto Co., Inc. Culture medium for proliferating stem cell, which contains sulfated compound
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
KR102650035B1 (ko) 2015-11-27 2024-03-20 마자리코바 우니베지타 내열성 fgf2 폴리펩타이드 및 그 용도
JP2021138648A (ja) * 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor

Also Published As

Publication number Publication date
DE69006947D1 (de) 1994-04-07
ATE102044T1 (de) 1994-03-15
US5189148A (en) 1993-02-23
IE902470A1 (en) 1991-02-13
NO902995L (no) 1991-01-08
AU632344B2 (en) 1992-12-24
HU904116D0 (en) 1990-12-28
EP0406856B1 (en) 1994-03-02
NO902995D0 (no) 1990-07-04
HU205862B (en) 1992-07-28
EP0406856A2 (en) 1991-01-09
CA2020654A1 (en) 1991-01-08
EP0406856A3 (en) 1991-04-10
DE69006947T2 (de) 1994-08-25
AU5879990A (en) 1991-01-10
ES2062206T3 (es) 1994-12-16
JPH04128239A (ja) 1992-04-28
FI903440A0 (fi) 1990-07-06
CN1049106A (zh) 1991-02-13
JP2536247B2 (ja) 1996-09-18
FI903440A7 (fi) 1991-01-08
HUT54895A (en) 1991-04-29

Similar Documents

Publication Publication Date Title
DK0406856T3 (da) Stabiliseret FGF-komposition og fremstilling heraf
EP0406274A4 (en) New, water soluble, antineoplastic derivatives of taxol
NO871333L (no) Kinolin-3-karboksylsyrederivater, fremgangsmaate til fremstilling og anvendelse derav.
DK167441C (da) Fremgangsmaade til fremstilling af blandet substituerede, enantiomer-rene 1,2-diacyl-sn-glycero-3-phosphocholiner og 1,2-diacyl-sn-glycero-3-phosphoethanolaminer
NO870512L (no) 1,4-benzoksazinderivater og fremgangsmaate for deres fremstilling.
NO922953D0 (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
NO903757L (no) Kitin.kitosan-oligomer med 2,5-anhydromannitol endegruppeeller 2,5-anhydromannose endegruppe og fremgangsmaate til fremstilling derav.
NO871052D0 (no) 1,1-disubstituerte cyklopropanderivater, fremgangsmaate til deres fremstilling og deres anvendelse.
KR0156686B1 (en) Pharmaceutical composition comprising aryl-substituted rhodanine derivatives
DK284988A (da) Fremgangsmaade til fremstilling af den 2,2-paracyclophandimer, der anvendes til fremstilling af paylen
MY103362A (en) Production of proteins in active forms
PT80752A (en) Process for preparing solid medicament formulations containing dihydropyridines
DE68900210D1 (de) Pyranobenzoxadiazolderivate, herstellung, verwendung und diese enthaltende zubereitungen.
NO892798L (no) Pyrazolyleterderivater, fremgangsmaate for fremstilling avdisse, preparater og anvendelse derav.
ES8607015A1 (es) Preparado solido de dihidropiridina
EP0390849A4 (en) Methyl cellulose pharmaceutical composition
DK379387A (da) Optisk rene 1,3-dioxenoner, fremgangsmaade til fremstilling deraf og anvendelse heraf
DK587689A (da) 2-azabicyclo(2,2,1)hept-5-en-2-eddikesyre og derivater deraf, deres fremstilling og anvendelse
DE69004151D1 (de) FR115224 enthaltende Zusammensetzung für eine parenterale Verabreichung.
ES2007265A6 (es) Un metodo para preparar conjugados de indol-portador biologicamente activos.
NO905244L (no) Fremgangsmaate for fremstilling av des(64,65)-proinsulin.
NO903484D0 (no) Substituerte pyrazinderivater og fremgangsmaate for deres fremstilling.
DE69104299D1 (de) Verfahren zur Herstellung von 2,6-Di-t-butyl-4-merkaptophenol.
MX17042A (es) (1) benzotiopirano (4,3-c)-pirazoles y procedimiento para su preparacion.
DK0661541T3 (da) Fremgangsmåde til fremstilling af langtidsstabile klare sera